Drug Profile
Silibinin
Alternative Names: SilybinLatest Information Update: 15 Oct 2021
Price :
$50
*
At a glance
- Originator Indena
- Class Antidotes; Antihyperlipidaemics; Antivirals; Chromans; Dioxins; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 18 Oct 2004 Preclinical trials in Prostate cancer in Italy (unspecified route)
- 18 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the Cancer pharmacodynamics section
- 23 Nov 2000 A preclinical study has been added to the Cancer therapeutic trials section